BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27564113)

  • 1. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
    Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
    Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
    Sidarovich V; De Mariano M; Aveic S; Pancher M; Adami V; Gatto P; Pizzini S; Pasini L; Croce M; Parodi F; Cimmino F; Avitabile M; Emionite L; Cilli M; Ferrini S; Pagano A; Capasso M; Quattrone A; Tonini GP; Longo L
    Mol Cancer Ther; 2018 Jul; 17(7):1405-1415. PubMed ID: 29695637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
    Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
    Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
    Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.
    Whittle SB; Patel K; Zhang L; Woodfield SE; Du M; Smith V; Zage PE
    Invest New Drugs; 2016 Dec; 34(6):685-692. PubMed ID: 27586230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib.
    Corallo D; Pastorino F; Pantile M; Mariotto E; Caicci F; Viola G; Ponzoni M; Tonini GP; Aveic S
    J Exp Clin Cancer Res; 2020 Sep; 39(1):195. PubMed ID: 32962733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
    Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
    Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.
    Singh A; Meier-Stephenson V; Jayanthan A; Narendran A
    Curr Cancer Drug Targets; 2017; 17(6):569-584. PubMed ID: 27875952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
    Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
    Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
    Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
    Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
    Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
    Geng X; Xie L; Xing H
    Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
    Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
    Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
    Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
    Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling.
    Liu C; Mu X; Wang X; Zhang C; Zhang L; Yu B; Sun G
    Molecules; 2019 Apr; 24(7):. PubMed ID: 30959969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
    Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
    Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
    Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
    Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
    Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.